The endothelin system is implicated in various human and animal glaucomas. Targeting the endothelin system has great promise as a treatment for human glaucoma, but the cell types involved and the exact mechanisms of action are not clearly elucidated. Here, we report a detailed characterization of the endothelin system in specific cell types of the optic nerve head (ONH) during glaucoma in DBA/2J mice. First, we show that key components of the endothelin system are expressed in multiple cell types. We discover that endothelin 2 (EDN2) is expressed in astrocytes as well as microglia/monocytes in the ONH. The endothelin receptor type A (Ednra) is expressed in vascular endothelial cells, while the endothelin receptor type B (Ednrb) receptor is expressed in ONH astrocytes. Second, we show that Macitentan treatment protects from glaucoma. Macitentan is a novel, orally administered, dual endothelin receptor antagonist with greater affinity, efficacy and safety than previous antagonists. Finally, we test the combinatorial effect of targeting both the endothelin and complement systems as a treatment for glaucoma. Similar to endothelin, the complement system is implicated in a variety of human and animal glaucomas, and has great promise as a treatment target. We discovered that combined targeting of the endothelin (Bosentan) and complement (C1qa mutation) systems is profoundly protective. Remarkably, 80% of DBA/2J eyes subjected to this combined inhibition developed no detectable glaucoma. This opens an exciting new avenue for neuroprotection in glaucoma.
Introduction
Glaucoma is one of the most common neurodegenerative diseases (Quigley, 1996) characterized by the death of retinal ganglion cells (RGCs) and degeneration of the optic nerve (reviewed in Burgoyne, 2011; Nickells et al., 2012) . The optic nerve head (ONH) is a key site in glaucoma (e.g., Anderson and Hendrickson, 1974; Quigley and Anderson, 1976; Anderson and Hendrickson, 1977; Quigley and Anderson, 1977; Quigley and Addicks, 1980; Howell et al., 2007a) . More effective therapies, particularly those that target damaging processes in the optic nerve head are required. A critical and early insult damages RGC axons in the ONH (Schlamp et al., 2006; Howell et al., 2007a; Burgoyne, 2011) . Nevertheless, the earliest processes that damage RGC axons are not well defined. To better understand these early stages, we performed gene expression profiling from DBA/2J mice, a widely used mouse model of glaucoma (Howell et al., 2011a (Howell et al., , 2012b . Our gene expression analyses identified a temporally ordered series of early glaucoma stages. Previous studies had suggested the importance of the endothelin system in glaucoma (reviewed in Chauhan, 2008; Good and Kahook, 2010; Prasanna et al., 2011) and our data showed that endothelin-2 (Edn2) was significantly upregulated compared to non-glaucoma eyes at early stages of the disease, prior to significant axon damage (Howell et al., 2011a) . Cumulatively, this data suggest that components of the endothelin system maybe critical in the early progression of glaucoma in the optic nerve head.
The endothelin system is comprised of three ligands (endothelin 1, EDN1; EDN2 and endothelin 3, EDN3) that interact with two receptors, endothelin receptor type A (EDNRA) and endothelin receptor type B (EDNRB) (Kedzierski and Yanagisawa, 2001 ). Endothelin ligands binding either to one or both of the endothelin receptors activate a variety of different responses within tissues (reviewed in Kedzierski and Yanagisawa, 2001) . Upregulation of components of the endothelin system is described in human glaucoma and in animal models relevant 
